• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Brainstorm adds UCal Irvine Medical Center to late-stage NurOwn trial

July 25, 2017 By Sarah Faulkner

BrainStorm Cell TherapeuticsBrainstorm Cell Therapeutics (NSDQ:BCLI) said today that it inked an agreement with the University of California Irvine Medical Center to enroll patients in the Phase III trial of its NurOwn mesenchymal stem cell-based platform for amyotrophic lateral sclerosis.

This marks the third medical center to work with Brainstorm to enroll patients in the late-stage pivotal trial. The company said last week that Massachusetts General Hospital and California Pacific Medical Center both agreed to participate in the trial.

“We are privileged to have UCI and Dr. Goyal join our pivotal Phase III study of NurOwn,” Brainstorm’s chief executive & president Chaim Lebovits said in prepared remarks. “Adding UCI as an enrolling center with Dr. Goyal as principal investigator will make the treatment more accessible to patients in California, and we welcome the opportunity to work with this prestigious institution.”

“NurOwn is a very promising treatment with compelling Phase II data in patients with ALS; we look forward to further advancing it in clinical development and confirming the therapeutic benefit with Brainstorm,” Dr. Namita Goyal, director of the ALS Clinic in the Neuromuscular Medicine Fellowship and Neuromuscular Diagnostic Laboratory at UCI, added.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Featured, Regenerative Medicine, Stem Cells, Wall Street Beat Tagged With: Brainstorm Cell Therapeutics

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS